e-learning
resources
Barcelona 2013
Monday, 09.09.2013
Respiratory infections: a combination of problems needing early treatment
Login
Search all ERS
e-learning
resources
Disease Areas
Airways Diseases
Interstitial Lung Diseases
Respiratory Critical Care
Respiratory Infections
Paediatric Respiratory Diseases
Pulmonary Vascular Diseases
Sleep and Breathing Disorders
Thoracic Oncology
Events
International Congress
Courses
Webinars
Conferences
Research Seminars
Journal Clubs
Publications
Breathe
Monograph
ERJ
ERJ Open Research
ERR
European Lung White Book
Handbook Series
Guidelines
All ERS guidelines
e-learning
CME Online
Case reports
Short Videos
SpirXpert
Procedure Videos
CME tests
Reference Database of Respiratory Sounds
Radiology Image Challenge
Brief tobacco interventions
EU Projects
VALUE-Dx
ERN-LUNG
ECRAID
UNITE4TB
Disease Areas
Events
Publications
Guidelines
e-learning
EU Projects
Login
Search
Procalcitonin (PCT) and C-reactive protein (CRP) as markers of the differential diagnosis of severe community acquired pneumonia (sCAP)
O. Bielosludtsev, K. Bielosludtseva, O. Nazarenko (Dnipropetrovsk, Ukraine)
Source:
Annual Congress 2013 –Respiratory infections: a combination of problems needing early treatment
Session:
Respiratory infections: a combination of problems needing early treatment
Session type:
Thematic Poster Session
Number:
2714
Disease area:
Respiratory critical care, Respiratory infections
Rating:
You must
login
to grade this presentation.
Share or cite this content
Citations should be made in the following way:
O. Bielosludtsev, K. Bielosludtseva, O. Nazarenko (Dnipropetrovsk, Ukraine). Procalcitonin (PCT) and C-reactive protein (CRP) as markers of the differential diagnosis of severe community acquired pneumonia (sCAP). Eur Respir J 2013; 42: Suppl. 57, 2714
You must
login
to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.
Member's Comments
No comment yet.
You must
Login
to comment this presentation.
Related content which might interest you:
Management of severe community acquired pneumonia – ERS guidelines
Predictive indexes in prolonged weaning of mechanical ventilation due to tracheostomy in patients with COVID-19 pneumonia
Lane-hamilton syndrome and CCF: a fatal association
Related content which might interest you:
C-reactive protein (CRP) as a marker of disease severity in community acquired pneumonia patients with sepsis
Source: Annual Congress 2012 - Infections and sepsis in the ICU
Year: 2012
C-reactive protein as severity biomarker in patients with community-acquired pneumonia (CAP)
Source: Eur Respir J 2005; 26: Suppl. 49, 545s
Year: 2005
Changes in levels of inflammatory markers (procalcitonin, C-reactive protein) in pregnant with community-acquired pneumonia (CAP)
Source: International Congress 2016 – Community-acquired pneumonia: risk classes and management issues
Year: 2016
Surfactant protein D (SPD) and C-reactive protein (CRP) in patient with low respiratory tract infections (LRTI)
Source: Annual Congress 2013 –Lung infections: a clinical point of view
Year: 2013
Prognosis value of initial C-reactive protein (CRP) assay in patients with community acquired pneumonia
Source: Annual Congress 2008 - Community-acquired pneumonia: prognosis, complications and prevention
Year: 2008
C-reactive protein (CRP) utility in severe community-acquired pneumonia (SCAP) prognosis
Source: Annual Congress 2011 - Biomarkers and outcomes of community-acquired pneumonia
Year: 2011
Can procalcitonin or C-reactive protein predict supporative lung complications and ARDS at severe community-acquired pneumonia (CAP)?
Source: International Congress 2016 – Community-acquired pneumonia: from prevention to treatment
Year: 2016
The discriminatory value of procalcitonin (PCT) and C-reactive protein (CRP) levels in HIV-seropositive patients presenting with community acquired pneumonia (CAP) due to pulmonary tuberculosis (PTB) compared with patients with pneumococcal pneumonia
Source: Eur Respir J 2004; 24: Suppl. 48, 241s
Year: 2004
Individual monitoring of procalcitonin and C-reactive protein levels as a criterion for cancel of antibiotic therapy in patients with severe community-acquired pneumonia
Source: Annual Congress 2013 –Biomarkers, diagnosis and outcome of respiratory infections
Year: 2013
C-reactive protein (C-RP) in patients with chronic heart failure (CHF) and community-acquired pneumonia (CAP): usefulness to guide antibiotic prescription
Source: International Congress 2018 – Predicting the future: biomarkers of respiratory infection
Year: 2018
Serum C-reactive protein (CRP) as a marker of the severity and prognosis of ventilator-associated pneumonia (VAP)
Source: Annual Congress 2007 - Diagnostic markers and therapy in hospital-acquired pneumonia
Year: 2007
Does the serum C-reactive protein (CRP) predict adverse outcomes in patients admitted with community acquired pneumonia?
Source: Annual Congress 2011 - Biomarkers and outcomes of community-acquired pneumonia
Year: 2011
Could procalcitonin (PCT) be a marker of effectiveness of antibiotic treatment (ABT) in pregnant with not severe community-acquired pneumonia (CAP)?
Source: International Congress 2015 – Healthcare organisation and appropriateness in lung disorders
Year: 2015
Surfactant protein D (SPD) and C-reactive protein (CRP) levels in patients (pts) with community acquired pneumonia (CAP) during the treatment program
Source: International Congress 2014 – Clinical problems in acute and chronic lung diseases
Year: 2014
Serum procalcitonin (PCT) as a marker of the severity and prognosis of ventilator-associated pneumonia (VAP)
Source: Annual Congress 2007 - Diagnostic markers and therapy in hospital-acquired pneumonia
Year: 2007
Diagnostic accuracy of lipopolysaccharide-binding protein (LBP), fibrinogen and C-reactive protein (CRP) in differentiating pneumonia from acute bronchitis in primary care
Source: Annual Congress 2008 - Wider aspects of managing respiratory disease in primary care
Year: 2008
C-reactive protein (CRP), an early prognostic tool in community acquired pneumonia (CAP)
Source: Annual Congress 2009 - Impact of biomarkers in the management of community-acquired pneumonia
Year: 2009
C-reactive protein (CRP) at admission: is it really usefull in COVID-19 pneumonia?
Source: Virtual Congress 2021 – COVID - 19 biomarkers
Year: 2021
The prognostic value of consecutive C-reactive protein measurements in community acquired pneumonia
Source: International Congress 2015 – CAP: prognostic factors in frail patients
Year: 2015
Diagnostic and prognostic utility of procalcitonin (PCT) measurements in patients with hospitalized community-acquired pneumonia (CAP)
Source: Annual Congress 2009 - Assessment of severity in respiratory infections: severity scales and biomarkers
Year: 2009
We use cookies on our website to give you the most relevant experience by remembering your preferences and repeat visits. By clicking "Accept", you consent to the use of the cookies.
Accept